AFT Pharmaceuticals is now registered for the sale of its long-lasting hand sanitiser Crystawash Extend in China.
AFT also has signed new licence agreements for the intravenous dose form of its Maxigesic pain relief medicine as it continues to build momentum in its international business.
AFT Managing Director Hartley Atkinson explained that "these licensing, registration and distribution agreements and the recent launches will add to the momentum we are seeing in the company's international business.
"As a result of these launches and recent sales, AFT will enter the new financial year with Maxigesic sold in 61 countries in various dose forms, 15 more than where we were in Mar 2022, although just short of our target of 63 countries.
"We are pleased with the progress made in realising the potential of our Maxigesic intellectual property.
"Additionally, we are pleased to achieve our first product registration in Mainland China and further registrations are pending."
The Chinese National Medical Products Administration approved Crystawash Extend 24-hour long-lasting hand sanitiser which allows AFT to sell into retail stores in mainland China.
Crystawash Extend sanitises and protects against 99.99% of germs for up to 24 hours, and is non-toxic and alcohol-free.
AFT will commercialise this product range within the next six to 12 months into mainland China.
The privately owned Swiss pharmaceutical company Labatec has licensed the intravenous form, Maxigesic IV, in Switzerland.
Labatec and AFT are aiming for registration and launch of the medicine - a treatment for mild-to-moderate pain for use post-operatively in hospitals when patients cannot take a medicine orally - in the next 12 to 18 months.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Mar 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Mar 23
